

March 10, 2016
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President & Chief Executive Officer

**Notice concerning Partial Amendment to the Articles of Incorporation
 and Nomination of Director Candidates**

SymBio Pharmaceuticals Limited (“the Company”) announces that at a Board of Directors Meeting held today, it has decided to submit, for discussion at the 11th Ordinary General Meeting of Shareholders that will be held on March 30, 2016, (the “Shareholders Meeting”) a proposal on the “Partial Amendment to the Articles of Incorporation” and “Election of six (6) Directors.”

1. Partial Amendment to the Articles of Incorporation

(1) Reason for the amendment

Following enforcement of the “Act for Partial Revision of the Companies Act” (Act No. 90 of 2014), it has become possible for the Company to enter into a liability limitation agreement with Directors who do not engage in business execution and with Audit & Supervisory Board members who are not outside members of the Audit & Supervisory Board. Accordingly, in order for these officers to be able to fully play their expected roles, we propose to partially amend Article 29 (Exemption from Liability of Directors) and Article 37 (Exemption from Liability of Audit & Supervisory Board Members) of the current Articles of Incorporation. With respect to amendment to Article 29 of the current Articles of Incorporation, we have obtained approval from each Audit & Supervisory Board Member.

(2) Proposed amendment

Details of the proposed amendment are as follows.

(Amended portions shown with underlines)

Current Articles of Incorporation	Proposed Amendment
Chapter 4 Directors and Board of Directors (Exemption from Liability of Directors) Article 29 <p style="text-align: center;">(Provision omitted)</p>	Chapter 4 Directors and Board of Directors (Exemption from Liability of Directors) Article 29 <p style="text-align: center;">(Same as the current version)</p>
2. The Company may enter into an agreement with <u>Outside</u> Directors with respect to the liability in Article 423, Paragraph 1 of the Companies Act, setting forth that the higher of the amount of 1,000,000 yen or above set forth	2. The Company may enter into an agreement with Directors (<u>excluding those who engage in business execution</u>) with respect to the liability in Article 423, Paragraph 1 of the Companies Act, setting forth that the higher

in advance or the amount set forth in laws and regulations at the maximum shall be borne, in cases where such <u>Outside</u> Directors performed their duties in good faith and without gross negligence.	of the amount of 1,000,000 yen or above set forth in advance or the amount set forth in laws and regulations at the maximum shall be borne, in cases where such Directors performed their duties in good faith and without gross negligence.
---	--

Current Articles of Incorporation	Proposed Amendment
<p>Chapter 5 Audit & Supervisory Board Members and Audit & Supervisory Board (Exemption from Liability of Audit & Supervisory Board Members) Article 37 (Provision omitted)</p> <p>2. The Company may enter into an agreement with <u>outside members of the Audit & Supervisory Board</u> with respect to the liability in Article 423, Paragraph 1 of the Companies Act, setting forth that the higher of the amount of 1,000,000 yen or above set forth in advance or the amount set forth in laws and regulations at the maximum shall be borne, in cases where such <u>outside members of the Audit & Supervisory Board</u> performed their duties in good faith and without gross negligence.</p>	<p>Chapter 5 Audit & Supervisory Board Members and Audit & Supervisory Board (Exemption from Liability of Audit & Supervisory Board Members) Article 37 (Same as the current version)</p> <p>2. The Company may enter into an agreement with <u>Audit & Supervisory Board Members</u> with respect to the liability in Article 423, Paragraph 1 of the Companies Act, setting forth that the higher of the amount of 1,000,000 yen or above set forth in advance or the amount set forth in laws and regulations at the maximum shall be borne, in cases where such <u>Audit & Supervisory Board Members</u> performed their duties in good faith and without gross negligence.</p>

2. Nomination of Candidates for the Board of Directors

As the term of office for six (6) Directors shall expire at the closing of the Shareholders Meeting, we hereby propose the election of six (6) Directors as below.

Name	Class	Current Title
Fuminori Yoshida	Re-nomination	Representative Director, President & CEO
Lowell Sears	Re-nomination	Director
George Morstyn	Re-nomination	Director
Milton Grannatt	Re-nomination	Director
George Vandeman	Re-nomination	Director
Naoko Iino	Newly nominated	—

* Director candidates Mr. Lowell Sears, Dr. George Morstyn, Dr. Milton Grannatt, Mr. George Vandeman and Ms. Naoko Iino are candidates for the position of Outside Director.

3. Profile of Candidates

Name (Date of Birth)	Career Summary	
Naoko Iino (June 10, 1960)	July, 2000	Director and Executive Vice President, Medical Planet Inc., Watakyu Seimoa Group
	March, 2005	Director and President, Medical Creation Co., Ltd., Humantrust Group Co., Ltd.
	February, 2007	Representative Director and President, Japan Medical Information Research Institute Inc.
	April, 2007	Part-time lecturer, University of Occupational and Environmental Health (current)
	March, 2010	Director and Senior Executive Officer, tella, Inc.
	June, 2014	Assistant Managing Director, Tokyo University of Science (current)

* We request the election of Ms. Naoko Iino as an Outside Director in order to seek her advice and opinion on the Company's management, as she possesses an objective perspective independent from the Company's management engaged in business operations, and has the capacity to leverage her wealth of knowledge and experience in senior management.

4. Resignation from the Board of Directors

Name	Class	Current Title
Takako Ebata	Resigned	Director

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125